Baird Reiterates Outperform Rating on Cellectis (CLLS)

Baird analyst Madhu Kumar reiterated an Outperform rating and $10.00 price target on Cellectis (NASDAQ: CLLS).

The analyst commented: "Cellectis announced 3Q24 financials and provided business updates. Overall, we were encouraged by the updates as it appears that the AstraZeneca (AZN, not covered) research partnership is off to a strong start with three programs underway and meaningful revenues triggered to date, while the internal pipeline is progressing toward a pair of readouts from UCART22 and UCART20x22 in 2025. Looking ahead, we anticipate shares of Cellectis remain poised to move higher as the AstraZeneca partnership expands and the company provides updates from internal programs."

For an analyst ratings summary and ratings history on Cellectis click here. For more ratings news on Cellectis click here.

Shares of Cellectis closed at $1.76 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Bitmine Immersion Technologies plans $300 million preferred stock offering
• Some Glazer family members said to consider selling Manchester United plc (MANU) stake - Bloomberg